BMY-14802

BMY-14802
(IUPAC) ime
	1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
Klinički podaci
Identifikatori
CAS broj	105565-55-7
ATC kod	nije dodeljen
PubChem	108046
Hemijski podaci
Formula	C18H22F2N4O
Mol. masa	348.389 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2 ; Key: ZXUYYZPJUGQHLQ-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

BMY-14802 je lek sa antipsihotičkim dejstvom. On je antagonist sigma receptora, i agonist 5-HT_1A receptora.^[3]^[4]^[5]^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). „A role for sigma binding in the antipsychotic profile of BMY 14802?”. NIDA Research Monograph 133: 125–57. PMID 8232511.
↑ Vanecek SA, Essman WD, Taylor DP, Woods JH (January 1998). „Discriminative stimulus characteristics of BMY 14802 in the pigeon”. The Journal of Pharmacology and Experimental Therapeutics 284 (1): 1–9. PMID 9435153.
↑ Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (May 2009). „Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice”. Psychopharmacology 203 (4): 781–92. DOI:10.1007/s00213-008-1425-z. PMID 19052726.
↑ Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (July 2009). „The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism”. Psychopharmacology 204 (4): 743–54. DOI:10.1007/s00213-009-1505-8. PMC 2845289. PMID 19283364.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid8232511-3] Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). „A role for sigma binding in the antipsychotic profile of BMY 14802?”. NIDA Research Monograph 133: 125–57. PMID 8232511.

[pmid9435153-4] Vanecek SA, Essman WD, Taylor DP, Woods JH (January 1998). „Discriminative stimulus characteristics of BMY 14802 in the pigeon”. The Journal of Pharmacology and Experimental Therapeutics 284 (1): 1–9. PMID 9435153.

[pmid19052726-5] Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (May 2009). „Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice”. Psychopharmacology 203 (4): 781–92. DOI:10.1007/s00213-008-1425-z. PMID 19052726.

[pmid19283364-6] Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (July 2009). „The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism”. Psychopharmacology 204 (4): 743–54. DOI:10.1007/s00213-009-1505-8. PMC 2845289. PMID 19283364.

[1]

[2]

[3]

[4]

[5]

[6]